This investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously is being studied for obesity and type 2 diabetes management, with early-phase data showing promising results
As a standalone agent and in combination with semaglutide (the CagriSema regimen), it has shown statistically significant reductions in body weight and improvements across multiple cardiometabolic markers
Most people experience them occasionally, and they are usually temporary
For example, if you have a deficiency and need regular B12 injections, hydroxocobalamin can be given once every 3 months, whereas cyanocobalamin would need to be given every month
Women and omega-3 Fatty acids
Appetite suppression begins but is subtle